BioSpace News Archive

Mesa Laboratories, Inc., a global leader in the design and manufacturing of life science tools and critical quality control solutions, announced results for its first fiscal quarter ended June 30, 2023.

Biora Therapeutics, Inc. (Nasdaq: BIOR) today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary Curetis GmbH has signed an extended and continued research and development collaboration agreement with FIND.

Spero Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. ET to report its second quarter 2023 financial results.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2023 and provided a business update.

Shoreline Biosciences, Inc., a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells derived natural killer cells and macrophages, announced that it will participate in the 2023 Wedbush Pacgrow Healthcare Conference taking place August 8-9, 2023 in New York, NY.

Aardvark Therapeutics today reported receipt of a Rare Pediatric Disease Designation in Prader-Willi Syndrome (PWS) from the FDA for its lead program ARD-101.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.

IMUNON, Inc. announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, August 10, 2023 to discuss financial results for the second quarter and six-months ended June 30, 2023 and provide an update on its clinical development of IMNN-001 (formerly GEN-1).